<![CDATA[Psoriasis is a chronic immune-mediated disease affecting 1–3% of the population worldwide and often impairs quality of life, with moderate-to-severe cases requiring systemic therapy. Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor that modulates IL-23, IL-12, and type I interferon pathways, has emerged as a promising oral therapy. However, trial findings remain inconsistent, highlighting the need for systematic evaluation of its efficacy and safety versus placebo. A comprehensive literature search of PubMed, Scopus, Scilit, and ScienceDirect was performed to identify randomized controlled trials published up to 2025 comparing deucravacitinib with placebo in psoriasis. Risk of bias was assessed using the Cochrane RoB 2.0 tool, and meta-analysis was conducted with Rstudio with random effect model and REML estimator. Seven RCTs (n = 3,014) were included. Deucravacitinib significantly improved PASI-75 (OR = 9.85; 95% CI 5.11–19.01; p < 0.0001), PASI-90 (OR = 14.29; 95% CI 9.14–22.35; p < 0.0001), and PASI-100 (OR = 12.03; 95% CI 5.55–26.09; p < 0.0001), as well as sPGA 0/1 (OR = 14.28; 95% CI 9.30–23.62; p < 0.0001). Quality-of-life outcomes also improved: PSSD-0 (OR = 7.60; 95% CI 2.73–21.16; p = 0.0001) and DLQI 0/1 (OR = 6.27; 95% CI 4.68–8.41; p < 0.0001). Upper respiratory tract infection and acne were more frequent with deucravacitinib, while other adverse events were comparable to placebo. Meta-regression showed dose dependence for DLQI 0/1 (p = 0.02) and PSSD-0 (p = 0.01), but not for adverse events. Deucravacitinib demonstrates significant efficacy and acceptable safety in psoriasis treatment. Long-term studies are warranted to confirm its sustained safety profile. Keywords: Deucravacitinib, Psoriasis, TYK2 Inhibitor, Efficacy]]>
Copyrights © 2025
